Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study (Q28275227)

1

0 references

Rahul Remanan

3

0 references

Stefan Marklund

4

0 references

Daniel Benjamin

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

5

0 references

language of work or name

English

0 references

publication date

April 2013

0 references

published in

1 reference

Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

PubMed

volume

14

0 references

issue

3

0 references

page(s)

199-204

0 references

cites work

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Molecular biology of amyotrophic lateral sclerosis: insights from genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Mutant SOD1 forms ion channel: implications for ALS pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Superoxide dismutase in CSF from amyotrophic lateral sclerosis patients with and without CuZn-superoxide dismutase mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074

Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.724074